-20C

Store at

6439

## Cell Signaling **Gasdermin B Antibody** H. Orders: orders@cellsignal.com Support: Web:

info@cellsignal.com cellsignal.com

877-616-CELL (2355)

877-678-TECH (8324)

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

| Applications:<br>W, IP       | Reactivity:<br>H | <b>Sensitivity:</b><br>Endogenous  | <b>MW (kDa):</b><br>47  | Source/Isotype:<br>Rabbit   | <b>UniProt ID:</b><br>#Q8TAX9-1  | Entrez-Gene Id:<br>55876   |  |
|------------------------------|------------------|--|---|---|--|--|--|
| Product Usage<br>Information |                  | <b>Application</b><br>Western Blotting<br>Immunoprecipitation  |   |   | <b>Dilution</b><br>1:1000<br>1:100   |  |  |
| Storage                      |                  | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at –<br>20°C. Do not aliquot the antibody.   |   |   |  |  |  |
| Specificity/Sensitivity      |                  | Gasdermin B Antibody recognizes endogenous levels of total Gasdermin B protein.  |   |   |  |  |  |
| Source / Purification        |                  | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to<br>residues surrounding Leu96 of human Gasdermin B protein. Antibodies are purified by protein A and<br>peptide affinity chromatography.  |   |   |  |  |  |
| Background                   |                  | to play a role in inflami<br>downstream effector o<br>inflammasomes, multi<br>patterns (PAMPs) or da<br>caspase-1 and subsequ<br>was identified by two in<br>caspase-11/4/5, produc<br>intramolecular inhibito   | mation and cell de<br>of pyroptosis (1,2).<br>protein complexes<br>anger-associated n<br>uent cleavage of p<br>ndependent group<br>cing two fragment<br>ory interaction betw  | DMA, GSDMB, GSDMC, G<br>ath. Gasdermin D has be<br>Pyroptosis is a lytic type<br>assembled in response<br>nolecular patterns (DAM<br>ro-inflammatory cytokin-<br>s as a substrate of inflar<br>s: GSDMD-N and GSDMI<br>ween the N- and C-termi<br>s through the formation | een reported to hav<br>of cell death trigger<br>to pathogen-associ<br>Ps) that result in the<br>es IL-1β and IL-18 (Ξ<br>nmatory caspases,<br>D-C. Cleavage result<br>nal domains, allowin | e a critical role as a<br>red by<br>ated molecular<br>e activation of<br>3). Gasdermin D<br>caspase-1 and<br>s in release of an<br>ng the N-terminal |  |
|                              |                  | cancer has been associ<br>been associated with ir<br>found in the lung epith   | iated with metasta<br>mmune disorders<br>nelium associated v  | d to be upregulated in se<br>isis and poor prognosis (<br>including asthma (10,11)<br>with asthma. Gasdermin<br>omote Gasdermin D clea  | (8,9). In addition Ga<br>). Gasdermin B expr<br>B can also have a r  | sdermin B has<br>ession has also be  |  |
| Background R                 | eferences        | 1. Kayagaki, N. et al. (20<br>2. Shi, J. et al. (2015) <i>Na</i><br>3. Broz, P. and Dixit, V.N<br>4. Aglietti, R.A. et al. (20<br>5. Ding, J. et al. (2016) <i>N</i><br>6. Liu, X. et al. (2016) <i>N</i><br>7. Sborgi, L. et al. (2016)<br>8. Hergueta-Redondo,<br>9. Hergueta-Redondo,<br>10. Yu, J. et al. (2011) <i>P</i><br>11. Das, S. et al. (2016)<br>12. Chen, Q. et al. (2018) | ature 526, 660-5.<br>M. (2016) Nat Rev I<br>016) Proc Natl Aca<br>Nature 535, 111-6.<br>Jature 535, 153-8.<br><i>EMBO J</i> 35, 1766<br>M. et al. (2014) PL<br>M. et al. (2016) Or<br>rediatr Pulmonol 46<br>Proc Natl Acad Sci | <i>mmunol</i> 16, 407-20.<br>d <i>Sci USA</i> 113, 7858-63.<br>-78.<br><i>oS One</i> 9, e90099.<br><i>icotarget</i> 7, 56295-308.<br>5, 701-8.<br><i>i U S A</i> 113, 13132-7.  |  |  |  |
| Species Reacti               | vity             | Species reactivity is det  | termined by testin  | g in at least one approve   | ed application (e.g.,  | western blot).   |  |
| Western Blot E               | Buffer           | IMPORTANT: For weste<br>TBS, 0.1% Tween® 20 a  |   | membrane with diluted<br>shaking, overnight.  | primary antibody ir  | ז 5% w/v BSA, 1X   |  |
| Applications K               | ey               | W: Western Blotting IP   | : Immunoprecipita   | ation   |  |  |  |
| Cross-Reactivit              | ty Key           | H: Human   |   |   |  |  |  |

| Trademarks and Patents | Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.  |  |  |
|------------------------|--|--|--|
|                        | All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.  |  |  |
| Limited Uses           | Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST,<br>the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's<br>terms and conditions that are in addition to, or different from, those contained herein, unless<br>separately accepted in writing by a legally authorized representative of CST, are rejected and are of no<br>force or effect.  |  |  |
|                        | Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products. |  |  |